Evidence map›Paper›PMID 25311528›Full record

ArticleProteomics2015

Differential regulation of FGFR3 by PTPN1 and PTPN2.

Jonathan R St-Germain, Paul Taylor, Wen Zhang, Zhihua Li, Troy Ketela, Jason Moffat, Benjamin G Neel, Suzanne Trudel, Michael F Moran

Open access · greenAbstract read
In one paragraph

Article in Proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Roles of miR-210 in the pathogenesis of pre-eclampsia.Archives of medical science : AMS · 2019
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jonathan R St-GermainProgram in Molecular Structure and Function, Hospital for Sick Children, Toronto, Canada; Department of Molecular Genetics, University of Toronto, Canada.
Paul Taylor
Wen Zhang
Zhihua Li
Troy Ketela
Jason Moffat
Benjamin G Neel
Suzanne Trudel
Michael F Moran
Hospital for Sick Children · CAPrincess Margaret Cancer Centre · CAUniversity of Toronto · CA

Funding

SIGNAL TRANSDUCTION BY NON-TRANSMEMBRANE PTPSR01CA049152 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEEL, BENJAMIN G. · 1989 to 2020
$4.4M
CIHRNCI NIH HHS R01 CA049152
6 · The paper itself

Abstract

Aberrant expression and activation of FGFR3 is associated with disease states including bone dysplasia and malignancies of bladder, cervix, and bone marrow. MS analysis of protein-phosphotyrosine in multiple myeloma cells revealed a prevalent phosphorylated motif, D/EYYR/K, derived from the kinase domain activation loops of tyrosine kinases including FGFR3 corresponding to a recognition sequence of protein-tyrosine phosphatase PTPN1. Knockdown of PTPN1 or the related enzyme PTPN2 by RNAi resulted in ligand-independent activation of FGFR3. Modulation of FGFR3 activation loop phosphorylation by both PTPN1 and PTPN2 was a function of receptor trafficking and phosphotyrosine phosphatase (PTP) compartmentalization. The FGFR3 activation loop motif DYYKK(650) is altered to DYYKE(650) in the oncogenic variant FGFR3(K650E) , and consequently it is constitutively fully activated and unaffected by activation loop phosphorylation. FGFR3(K650E) was nevertheless remarkably sensitive to negative regulation by PTPN1 and PTPN2. This suggests that in addition to modulating FGFR3 phosphorylation, PTPN1 and PTPN2 constrain the kinase domain by fostering an inactive-state. Loss of this constraint in response to ligand or impaired PTPN1/N2 may initiate FGFR3 activation. These results suggest a model wherein PTP expression levels may define conditions that select for ectopic FGFR3 expression and activation during tumorigenesis.

Indexed as

Amino Acid SequenceCell Line, TumorEndocytosisGene Expression Regulation, NeoplasticGlycosylationHumansMolecular Sequence DataMultiple MyelomaPhosphorylationProtein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine Phosphatase, Non-Receptor Type 2Receptor, Fibroblast Growth Factor, Type 3RNA InterferenceProtein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine Phosphatase, Non-Receptor Type 2PTPN1 protein, humanPTPN2 protein, humanReceptor, Fibroblast Growth Factor, Type 3Activation loopCell biologyEndocytosisGlycosylationMultiple myelomaTrafficking

Identifiers

PMID25311528
PMCPMC5032629
OpenAlexW1973063878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.